Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 226 to 240 of 436 results for cardiovascular disease

  1. Sedation in under 19s: using sedation for diagnostic and therapeutic procedures (CG112)

    This guideline covers the assessment, preparation, training and monitoring needed when using sedation in people aged under 19. It aims to help healthcare professionals decide when sedation is the most clinically and cost effective option for reducing pain and anxiety during operations for children and young people.

    Clinical guideline
    Published
    15 December 2010
    View recommendations

    Sections for CG112

  2. VIDAvision for lung volume analysis in emphysema (MIB148)

    NICE has developed a medtech innovation briefing (MIB) on VIDAvision for lung volume analysis in emphysema .

    Medtech innovation briefing
    Published
    5 June 2018

  3. What is the improvement in the cost-effectiveness metrics for statin therapy in reducing CVD that can be obtained when using a complete individual patient-based outcomes meta-analysis data set compared with using published outcomes data?

    data. Source guidance details Comes from guidance Cardiovascular disease: risk assessment and reduction, including lipid modification

    Research recommendation
    Published
    9 June 2015

  4. Cardiovascular disease: risk assessment and reduction, including lipid modification (CG181)

    This guideline has been updated and replaced by NICE guideline NG238.

    Clinical guideline
    Published
    18 July 2014

  5. Indicator advisory committee members

    Read biographies for all members of NICE's indicator advisory committee.

  6. Indicator advisory committee members

    Read biographies for all members of NICE's indicator advisory committee.

  7. What is the effectiveness of age alone and other routinely available risk factors compared with the formal structured multifactorial risk assessment to identify people at high risk of developing CVD?

    risk. Source guidance details Comes from guidance Cardiovascular disease: risk assessment and reduction, including lipid modification

    Research recommendation
    Published
    9 June 2015

  8. Targeted-release budesonide for treating primary IgA nephropathy (TA937)

    Evidence-based recommendations on targeted-release budesonide (Kinpeygo) for treating primary immunoglobulin A (IgA) nephropathy in adults.

    Technology appraisal guidance
    Last updated
    9 October 2025
    View recommendations

    Sections for TA937

  9. What are the long-term outcomes of different management strategies for primary hyperparathyroidism? Which strategies are most cost effective?

    knowledge and experience, the committee agreed that the risk of recurrent disease after successful parathyroid surgery is very low and...

    Research recommendation
    Published
    25 October 2019

  10. What is the clinical and cost effectiveness of treatment (antithyroid drugs or radioactive iodine) for improving long-term health outcomes for people with subclinical hyperthyroidism?

    hyperthyroidism is persistent and appears to be caused by intrinsic thyroid disease. However, the committee noted that there is...

    Research recommendation
    Published
    10 February 2020

  11. Daratumumab in combination for treating newly diagnosed systemic amyloid light-chain amyloidosis (TA959)

    Evidence-based recommendations on daratumumab (Darzalex) for newly diagnosed systemic amyloid light-chain amyloidosis in adults.

    Technology appraisal guidance
    Published
    27 March 2024
    View recommendations

    Sections for TA959

  12. Mifamurtide for the treatment of osteosarcoma (TA235)

    Evidence-based recommendations on mifamurtide (Mepact) for treating osteosarcoma in people aged 2 to 30 years.

    Technology appraisal guidance
    Published
    26 October 2011
    View recommendations

    Sections for TA235

  13. DuraGraft for preserving vascular grafts (MIB184)

    NICE has developed a medtech innovation briefing (MIB) on DuraGraft for preserving vascular grafts .

    Medtech innovation briefing
    Published
    8 May 2019

  14. What is the efficacy and safety of COVID-specific antiviral drugs in combination with other COVID-specific antiviral drugs or COVID-specific neutralising monoclonal antibodies in people who do not need supplemental oxygen and are within 7 days of symptom onset?

    severe COVID-19 disease, including (but not limited to): • aged 60 or over• immunosuppression• obesity• hypertension• chronic lung...

    Research recommendation
    Published
    9 March 2022

  15. What is the efficacy and safety of remdesivir for people who have been vaccinated against COVID-19?

    severe COVID-19 disease, including (but not limited to): • aged 60 or over• immunosuppression• obesity• hypertension• chronic lung...

    Research recommendation
    Published
    9 March 2022